Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

被引：0
|
作者：
Schultz, R. [1 ]
Diakite, I. [2 ]
Carter, J. [2 ]
Snedecor, S. [2 ]
Turpin, R. [3 ]
机构：
[1] Takeda Pharmaceut USA Inc, Gastroenterol, Deerfield, IL USA
[2] Pharmerit Int, Gastroenterol, Bethesda, MD USA
[3] Takeda Pharmaceut USA Inc, Gastroenterol, Lake Zurich, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S508 / S508
页数：1
相关论文
共 50 条
  • [21] Adalimumab for Induction of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William J.
    Hommes, Daniel W.
    D'Haens, Geert R.
    Hanauer, Stephen B.
    Schreiber, Stefan
    Panaccione, Remo
    Fedorak, Richard N.
    Tighe, Mary Beth
    Huang, Bidan
    Lazar, Andreas
    GASTROENTEROLOGY, 2010, 138 (05) : S114 - S115
  • [22] Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
    Kim, Jae Hyun
    Cheon, Jae Hee
    GUT AND LIVER, 2016, 10 (02) : 162 - 163
  • [23] Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
    Michele R. Wilson
    Annika Bergman
    Helene Chevrou-Severac
    Ross Selby
    Michael Smyth
    Matthew C. Kerrigan
    The European Journal of Health Economics, 2018, 19 : 229 - 240
  • [24] Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Montoiro-Allue, Raquel
    Lopez-Del Val, Alejandro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 321 - 329
  • [25] Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom
    Wilson, Michele R.
    Bergman, Annika
    Chevrou-Severac, Helene
    Selby, Ross
    Smyth, Michael
    Kerrigan, Matthew C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2018, 19 (02): : 229 - 240
  • [26] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [27] Cost-effectiveness of vedolizumab vs. ustekinumab as first-line biologic in treatment sequencing for ulcerative colitis in Canada
    Kao, K. E.
    Zhou, J. Y.
    Mac, S.
    Martin, M.
    Johnston, K.
    Marshall, J. K.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1402 - I1402
  • [28] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [29] Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Lopez-Del Val, Alejandro
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 355 - 360
  • [30] COST-EFFECTIVENESS ANALYSIS OF VEDOLIZUMAB IN ANTI-TNF-NAIVE PATIENTS WITH MODERATE-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN JAPAN
    Hernandez, L. G.
    Kuwabara, H.
    Shah, A.
    Yamabe, K.
    Burnett, H.
    Koufopoulou, M.
    Iwakiri, R.
    VALUE IN HEALTH, 2019, 22 : S178 - S178
12345